Skip to main content

Table 2 Toxicity

From: Bevacizumab plus octreotide and metronomic capecitabine in patients with metastatic well-to-moderately differentiated neuroendocrine tumors: the xelbevoct study

 

Grade

 

0

1

2

3

No. of patients (%)

    

Hematologic

    

Neutropenia

40 (88.9)

3 (6.7)

2 (4.4)

 

Anemia

35 (77.8)

5 (11.1)

5 (11.1)

 

Non hematologic

    

Nausea/vomiting

29 (64.4)

13 (28.9)

3 (6.7)

 

Diarrhea

23 (51.1)

17 (37.8)

5 (11.1)

 

Stomatitis

40 (88.9)

4 (8.9)

1 (2.2)

 

Hand and foot syndrome

17 (37.8)

12 (26.7)

11 (24.4)

5 (11.1)

Onycholysis

43 (95.6)

2 (4.4)

  

Hypertension

27 (60.0)

16 (35.6)

2 (4.4)

 

Proteinuria

20 (44.4)

13 (28.9)

7 (15.6)

2 (4.4)

Hemorrhage

42 (93.7)

3 (6.7)

  

Thrombosis

43 (95.6)

2 (4.4)

  

Cardiac

44 (97.8)

1 (2.2)

  

Fever

34 (75.5)

11 (24.4)

  

Asthenia

27 (60.0)

15 (33.3)

3 (6.7)

Â